Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Revenue of Agios Pharmaceuticals, Inc. (AGIO)
Revenue in 2023 (TTM): $26.82 M
According to Agios Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $26.82 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Agios Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $26.82 M | $17.32 M | $-384,864,000 | $-352,088,000 | $-352,088,000 |
| 2022 | $14.24 M | $12.54 M | $-380,483,000 | $-231,801,000 | $-74,555,000 |
| 2021 | $ | $-18,777,000 | $-337,733,000 | $-356,510,000 | $1.6 B |
| 2020 | $203.2 M | $200.39 M | $-326,126,000 | $-327,370,000 | $-335,218,000 |
| 2019 | $117.91 M | $116.6 M | $-394,853,000 | $-411,472,000 | $-396,611,000 |
| 2018 | $94.39 M | $92.99 M | $-338,856,000 | $-346,028,000 | $-346,028,000 |
| 2017 | $43.01 M | $-249,670,000 | $-314,362,000 | $-314,670,000 | $-314,670,000 |
| 2016 | $69.89 M | $-150,271,000 | $-195,277,000 | $-198,471,000 | $-198,471,000 |
| 2015 | $59.12 M | $-82,708,000 | $-115,358,000 | $-117,732,000 | $-117,732,000 |
| 2014 | $65.36 M | $-35,013,000 | $-52,766,000 | $-53,930,000 | $-53,504,000 |
| 2013 | $25.55 M | $-28,954,000 | $-37,443,000 | $-38,828,000 | $-39,407,000 |
| 2012 | $25.11 M | $-15,931,000 | $-21,816,000 | $-22,926,000 | $-20,102,000 |
| 2011 | $21.84 M | $21.84 M | $-15,830,000 | $-16,499,000 | $-23,706,000 |